Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 697

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 16K
Chunk 697
---
  Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks...  

  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion...  

  Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the conso...  

  Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company ’ s ability to continue as a going concern for a r...  

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

/s/ PricewaterhouseCoopers Zhong Tian LLP

Shanghai, the People’ s Republic of China

March 19, 2025

F-58

Table of Contents

Shanghai Hutchison Pharmaceuticals Limited

Consolidated Income Statements

(in US$’000)

                                                   Year Ended December 31,                                
                                         Note                         2024           2023           2022  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────
  Revenue                                   5                      393,525        385,483        370,600  
  Cost of sales                                                  (107,001)      (101,122)       (89,487)  
  Gross profit                                                     286,524        284,361        281,113  
  Selling expenses                                               (152,004)      (150,717)      (144,979)  
  Administrative expenses                                         (16,923)       (16,821)       (14,108)  
  Research and development expenses                               (13,782)        (9,286)        (7,619)  
  Other net operating income                6                        5,155          5,027          2,126  
  Operating profit                          7                      108,970        112,564        116,533  
  Finance costs                            15                         (46)           (79)          (112)  
  Profit before taxation                                           108,924        112,485        116,421  
  Taxation charge                           8